




**Stem Cell
Network**

Powering
Regenerative
Medicine

**Réseau de
Cellules Souches**

Propulsons
la médecine
régénératrice



SCN's Incubation Investment Award (IIA) Application

INCUBATION INVESTMENT AWARD (IIA) APPLICATION PROCESS:

- SCN's Incubation Investment Award Program is targeted to Canadian pre-seed and seed-staged regenerative medicine companies.
- As described in the IIA Program Guidelines found on [SCN's website](#), pre-seed and seed-staged companies that would like to be considered for IIA, will undergo a two-staged evaluation and selection process:
 - Stage 1: Submission of the Stage 1 IIA Application Form and non-confidential pitch deck, for eligibility, company staging, and investment potential assessment
 - Stage 2: Confidential due diligence
- To enter Stage 1, companies must complete this application form and upload their non-confidential pitch deck by the submission deadline (Friday, September 26, 2025, at 11:59 p.m. Pacific Time). SCN will confirm receipt within 48 hours; **applicants are responsible for following up if no confirmation is received.**
- Submission of the Stage 1 Application Form and non-confidential pitch deck is mandatory. SCN will assess eligibility, stage of development, and the company's potential for success within the IIA Program.
- If you have additional questions:
 - Please refer to the Frequently Asked Questions posted on the [SCN's website](#)
 - View the informational webinar posted on [SCN's YouTube channel](#)
 - Email us at researchSCN@stemcellnetwork.ca
- IIA applications are encouraged from Indigenous people, women, people with disabilities, racialized people, and 2SLGBTQIA+ people.
- Applicants that are successful in moving from Stage 1 to Stage 2 of the IIA process will be notified by **Wednesday, October 22, 2025.**
- No reviewer feedback will be provided for Stage 1 of the application process. Only companies participating in Stage 2 of the application process will receive reviewer evaluation and feedback comments.

TIMELINE:

- Competition opens Monday, September 8, 2025, at which point all key information for the Stage 1 application process will be available on [SCN's website](#).
- Stage 1 application submission deadline is Friday, September 26, 2025, at 11:59 p.m. Pacific Time.
- Applicants will be notified by Wednesday, October 22, 2025, if they have been selected to move forward to Stage 2 of the application process.

STAGE 1 APPLICATION INSTRUCTIONS:

- Definitions and instructions are provided on a per question basis. **Contact researchSCN@stemcellnetwork.ca if you have questions.**
- Please ***do not*** include any confidential information or trade secrets during the Stage 1 application process.
- The IIA Program supports high-potential regenerative medicine companies at both pre-seed and seed stages. Some questions in the application are geared towards more mature companies; please answer these questions to the best of your ability. All information provided during the Stage 1 application process will be reviewed in detail again during the Stage 2 evaluation and selection process, for invited companies.
- Non-confidential pitch decks should be submitted in PDF format and should be 10 (min) to 20 (max) slides in length. Non-confidential pitch decks should describe, at minimum, the technology, the team, and refer to the company strategy to advance the technology, and to advance the company (e.g. timelines, financing requirements, etc.).

Incubation Investment Award – Stage 1 Application

Section 1: Company Information

	Question	Description - Required
1a	Company name	
1b	Company location (headquarters, and location of any additional sites)	
1c	What is the date of company incorporation? (YYYY-MM-DD)	
1d	Where was the company incorporated?	
1e	First and Last name of primary applicant	
1f	Primary applicant company role	
1g	Primary applicant email address	
1h	Primary applicant phone number	
1i	Company website URL	
1j	Company 1-liner: A one sentence layman description of your company	
1k	Company 1-paragraph pitch: A one paragraph layman pitch of your company for a prospective investor	

Section 2: Eligibility Assessment and Company Staging

In the space provided below, please answer each of the questions with a Yes or No (if applicable), and if requested, provide a clarifying explanation. Replace the instruction text in square brackets with your answer. Applicants are encouraged to provide concise, complete answers.

	Question	Yes/No	Explanation
2a	Does your company and product focus on regenerative medicine?	[Yes/No]	[In no more than 200 words, provide a clear description of how the company and technology have a regenerative medicine alignment. Please refer to and make reference to the definition of regenerative medicine eligible companies/technologies provided in the IIA Program Guidelines on the SCN website.]
2b	Is your company a for-profit entity, incorporated in Canada?	[Yes/No]	[A Canadian company is a commercial enterprise that is incorporated pursuant to the laws of Canada and has ongoing business activities in Canada. If your company is incorporated provincially, please indicate in which province. Explain how your company is incorporated in less than 50 words.]
2c	Is your company >51% Canadian owned?	[Yes/No]	[Indicate % Canadian owned.]
2d	Have you filed intellectual property (IP) to protect your invention? If yes, does the company have commercialization rights to the IP (a license, or an assignment of rights)?	[Yes/No]	[In less than 200 words, provide details]
2e	How many full-time equivalent employees does your company have working to advance the company?	N/A	[Provide the number of full-time equivalent employees. Salaried employees paid from the company, employees paid from grants and vested contributors should all be listed. Summer students and co-op students should not be counted.]
2f	Please indicate your company Technology Readiness Level.	N/A	[Indicate the TRL and provide justification and rationale in less than 100 words. Please refer to the IIA Program Guidelines on SCN's website , for TRL reference information, also found here.]
2g	How much total financing (CAD) has your company secured since incorporation, from all sources?	N/A	[List the total amount of funding received to date, in CAD. For each source of funding, please also list date awarded, amount awarded, and source of funds. Of note, 'all sources' refers to company

			focused grant funding, friends and family financing, angel investment, family office investment, institutional investment, venture capital investment.]
--	--	--	---

Section 3: Technology Evaluation

In the space provided below, please answer each of the questions with a Yes or No (if applicable), and if requested, provide a clarifying explanation. Replace the instruction text in square brackets with your answer. Applicants are encouraged to provide concise but complete answers.

	Question	Yes/No	Explanation
3a	Describe your technology, and the problem you are trying to solve with your technology.	N/A	[In fewer than 250 words, briefly describe your technology and outline the need and challenge that is being addressed with your technology. Make reference to why others have failed in the past to solve the problem, if relevant.]
3b	Describe the market competition, if relevant, and how your technology has a competitive edge relative to key competitors.	N/A	[In fewer than 100 words, list your competitors, and how your technology is different/better.]
3c	Provide a one-paragraph non-confidential summary of the data you have on hand that convinces you that your technology can solve the problem.	N/A	[Provide your written summary in no more than 500 words. Do not include data figures here – relevant figures can be included in the non-confidential pitch deck.]
3d	How will your company innovation lead to a significant health impact and in what disease, illness, or injury areas is it targeted to?	N/A	[In fewer than 200 words, describe how it will lead to significant impact.]
3e	How many patent applications have you filed/licensed to protect	N/A	[Provide the number of patent applications filed, and their status (e.g., PCT vs. National Phase).]

	your technology and what is their status?		
3f	Do you have an IP strategy established?	[Yes/No]	[Outline the strategy in fewer than 200 words.]
3g	Has your team published any literature on the technology/innovation?	[Yes/No]	[If yes, please list all relevant publications.]
3h	Has your technology/innovation been awarded any prizes or recognition?	[Yes/No]	[If yes, please list awards or recognitions]

Section 4: Team Evaluation

In the space provided below, please answer each of the questions with a Yes or No (if applicable), and if requested, provide a clarifying explanation. Replace the instruction text in square brackets with your answer. Applicants are encouraged to provide concise but complete answers.

	Question	Yes/No	Explanation
4a	Provide the list of company co-founders and management team members.	N/A	[Provide their name, indicate if co-founder and/or management team member, affiliation, % time working for the company, and company title, if applicable. Please ensure its clear, if the co-founder is also taking a role as a company management team member.]
4b	Other than company co-founders and Board members, name all employees, vested contributors, consultants, and advisors that are supporting the company.	N/A	<p>[Provide a list of contributors, and for each of them, please also indicate: % of time dedicated to the company, their title, if applicable, if they are scientific focused or business focused, and if/how they are compensated. Examples shown below:</p> <ol style="list-style-type: none"> 1. Joe Smith: <5%, Business Advisor, Business Focus, Shares of the company 2. Jane Black: 50%, Sr. Scientist, Scientific Focus, paid from grant 3. Tom White: 100%, Sr. Scientist, Scientific Focus, paid from company

			4. Suzie Wang: <10%, Consultant, Business focus, paid from company]
4c	Do any of the co-founders, or management team members have biotech/pharma experience?	[Yes/No]	[If yes, provide team member names and details of the biotech/pharma experience, in less than 200 words.]
4d	Does the company have a Board of Directors in place?	[Yes/No]	[If yes, provide their names and affiliations.]
4e	Have any of the co-founders or management team members participated in any entrepreneurial training programs?	[Yes/No]	[If yes, describe who and the training they have received, in less than 100 words.]
4f	Has the company participated in any pitch competitions?	[Yes/No]	[If yes, list the pitch competitions, and the outcome.]

Section 5: Product Development Evaluation

In the space provided below, please answer each of the questions with a Yes or No (if applicable), and if requested, provide a clarifying explanation. Replace the instruction text in square brackets with your answer. Applicants are encouraged to provide concise but complete answers.

	Question	Yes/No	Explanation.
5a	Have you established a clinical development plan?	[Yes/No]	[If yes, provide details in less than 200 words.]
5b	Have you performed a manufacturability assessment or any pilot or GMP manufacturing for your technology?	[Yes/No]	[If yes, provide details in less than 200 words. Of note, a manufacturability assessment refers to a small-scale lab test, that would indicate that your product is manufacturable. A pilot manufacturing study is a small-scale experiment, that provides data to support how your product may be manufactured for the clinic; GMP manufacturing refers to clinical-grade product made at scale, in a clean room.]

5c	Have you assessed the safety/toxicity of your technology yet?	[Yes/No]	[If yes, provide details in less than 100 words.]
5d	Have you received feedback from any regulatory agencies (e.g., Health Canada, FDA, EMA) on your development strategy?	[Yes/No]	[If yes, provide details in less than 100 words.]
5e	In what quarter/year do you anticipate starting your first clinical trial?	N/A	[Enter a date formatted YYYY-QX]

Section 6: Corporate Evaluation

In the space provided below, please answer each of the questions with a Yes or No (if applicable), and if requested, provide a clarifying explanation. Replace the instruction text in square brackets with your answer. Applicants are encouraged to provide concise but complete answers.

	Question	Yes/No	Explanation
6a	Is your company actively fundraising?	[Yes/No]	[If yes, provide the following details: 1. Amount of funding you are seeking, 2. Target investor class (e.g., angels vs. VC), 3. Progress made and 4. Anticipated close date.]
6b	Have you received any feedback from institutional (venture capital) investors?	[Yes/No]	[Simply indicate Yes/No]
6c	Describe the milestones your company needs to achieve over the next 24 months, the associated timelines and budget (CAD) required to achieve them.	N/A	[List out specific milestones, the timeline to achieve them, and the budget required to achieve them. Only list milestones that are associated with company value creation.]

6d	What proportion of the budget required (as listed for 6c) is i) already secured, ii) not yet secured (part of an active fundraising round), and iii) are you requesting from SCN?	N/A	[Please breakdown the 24-month budget amount listed in 6c in each of these three categories. For example, total budget of 2M: i) 500,000, ii) 1,000,000, iii) 500,000. Of note, pre-seed staged companies are eligible for \$250,000 to \$500,000 whereas seed staged companies are eligible for \$500,000 to \$1,000,000.]
6e	Have you received any feedback from biotech or pharma stakeholders?	[Yes/No]	[If yes, describe the feedback (non-confidentially) in fewer than 300 words]
6f	Do you have any active opportunities or collaborations ongoing with biotech or pharma partners?	[Yes/No]	[If yes, explain (non-confidentially) in fewer than 100 words.]
6g	Has your company been supported by any incubator, or accelerator programs?	[Yes/No]	[Explain in fewer than 50 words.]
6h	Has SCN ever supported research associated with your company and the product you are developing?	[Yes/No]	[If yes, describe when and through which program/award in fewer than 200 words.]

Section 7: Non-Confidential Pitch Deck Submission

	Question	Explanation
7a	Upload your non-confidential Pitch Deck PDF.	Pitch decks should be submitted in PDF format with the filename structure: "CompanyName_ApplicantLastName_PitchDeck.PDF". PDF file size must be 50Mb or less.